The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer.
Ma CX, Luo J, Freedman RA, Pluard TJ, Nangia JR, Lu J, Valdez-Albini F, Cobleigh M, Jones JM, Lin NU, Winer EP, Marcom PK, Thomas S, Anderson J, Haas B, Bucheit L, Bryce R, Lalani AS, Carey LA, Goetz MP, Gao F, Kimmick G, Pegram MD, Ellis MJ, Bose R.
Ma CX, et al.
Clin Cancer Res. 2022 Apr 1;28(7):1258-1267. doi: 10.1158/1078-0432.CCR-21-3418.
Clin Cancer Res. 2022.
PMID: 35046057
Clinical Trial.